A Two Week Nitazoxanidebased Quadruple Regimen

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Helicobacter pylori (H. pylori) infection is a global health problem as it is associated with peptic ulcers, chronic gastritis, duodenitis, and stomach cancer.

Therefore, the eradication of the pathogen is of critical importance to reduce H. pylori-related complications .

However, due to increasing antibiotic resistance, eradication of Helicobacter pylori has become more challenging. With a great decline in the eradication rate of standard triple therapy for Helicobacter pylori to below 70% in many countries.

Treatment with triple therapy, which is the most frequently recommended, fails to eradicate H. pylori in approximately 20% of cases .

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Treatments: Doxycycline; Levofloxacin; Nitazoxanide; Ofloxacin; Omeprazole

Criteria

Inclusion Criteria:

• Patients with helicobacter infection.

• in whom the standard triple therapy (clarithromycin-based triple therapy) failed

Exclusion Criteria:

• Patients under 18 or over 65 years of age.

• Those with co-existing serious illnesses such as liver cirrhosis, uremia and gastrointestinal malignancies

• pregnancy/lactation

• having contraindication or allergy to any of the study drugs